Loading clinical trials...
Loading clinical trials...
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 5 LDE225 for Patients With PTCH1 or SMO Mutated Tumors
Conditions
Interventions
LDE225
Locations
10
United States
University of California Davis Cancer Center UC Davis Cancer (3)
Sacramento, California, United States
Rocky Mountain Cancer Centers RMCC - Aurora
Greenwood Village, Colorado, United States
Lurie Children's Hospital of Chicago Developmental Therapeutics
Chicago, Illinois, United States
Minnesota Oncology Hematology, P.A. Southdate Medical Center
Minneapolis, Minnesota, United States
Cleveland Clinic Foundation Cleveland Clinic (19)
Cleveland, Ohio, United States
Sanford Research Sanford Health
Sioux Falls, South Dakota, United States
Start Date
February 1, 2014
Primary Completion Date
March 1, 2015
Completion Date
March 1, 2015
Last Updated
May 2, 2016
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions